

## Biological Chemistry ‘Just Accepted’ Papers

**Biological Chemistry ‘Just Accepted’ Papers** are papers published online, in advance of appearing in the print journal. They have been peer-reviewed, accepted and are online published in manuscript form, but have not been copy edited, typeset, or proofread. Copy editing may lead to small differences between the Just Accepted version and the final version. There may also be differences in the quality of the graphics. When papers do appear in print, they will be removed from this feature and grouped with other papers in an issue.

**Biol Chem ‘Just Accepted’ Papers** are citable; the online publication date is indicated on the Table of Contents page, and the article’s Digital Object Identifier (DOI), a unique identifier for intellectual property in the digital environment (e.g., 10.1515/hsz-2011-xxxx), is shown at the top margin of the title page. Once an article is published as **Biol Chem ‘Just Accepted’ Paper** (and before it is published in its final form), it should be cited in other articles by indicating author list, title and DOI.

After a paper is published in **Biol Chem ‘Just Accepted’ Paper** form, it proceeds through the normal production process, which includes copy editing, typesetting and proofreading. The edited paper is then published in its final form in a regular print and online issue of **Biol Chem**. At this time, the **Biol Chem ‘Just Accepted’ Paper** version is replaced on the journal Web site by the final version of the paper with the same DOI as the **Biol Chem ‘Just Accepted’ Paper** version.

### Disclaimer

**Biol Chem ‘Just Accepted’ Papers** have undergone the complete peer-review process. However, none of the additional editorial preparation, which includes copy editing, typesetting and proofreading, has been performed. Therefore, there may be errors in articles published as **Biol Chem ‘Just Accepted’ Papers** that will be corrected in the final print and online version of the Journal. Any use of these articles is subject to the explicit understanding that the papers have not yet gone through the full quality control process prior to advanced publication.

## Review

# Galectins: new agonists of platelet activation

Mirta Schattner<sup>1,\*</sup> and Gabriel A. Rabinovich<sup>2,3</sup>

<sup>1</sup>Laboratory of Experimental Thrombosis, Institute of Experimental Medicine (IMEX/CONICET), National Academy of Medicine, C1425, Buenos Aires, Argentina

<sup>2</sup>Laboratory of Immunopathology, Institute of Biology and Experimental Medicine (IBYME/CONICET), C1428, Buenos Aires, Argentina

<sup>3</sup>Laboratory of Structural and Functional Glycomics, School of Exact and Natural Sciences, University of Buenos Aires, C1428, Buenos Aires, Argentina

\*Corresponding author

e-mail: mschattner@hotmail.com

## Abstract

Platelet activation at sites of vascular injury leads to the formation of a hemostatic plug and is crucial for hemostasis. However, uncontrolled platelet activation may lead to the formation of occlusive thrombi. Several soluble or matricellular proteins can activate platelets. In this article we review recent advances on the role of galectins in platelet physiology. Either in soluble or immobilized form, these endogenous glycan-binding proteins trigger platelet activation through modulation of discrete signaling pathways. We discuss the role of platelet-galectin interactions not only in hemostasis, but also in chronic inflammation, atherosclerosis and cancer.

**Keywords:** platelets, galectins, hemostasis, atherosclerosis, cancer, inflammation.

## Introduction: platelets

Platelets are anucleated cell fragments released from megakaryocytes. The primary role of platelets is to initiate and maintain haemostasis. However, their function is not limited to thrombosis, and extends into physiological processes such as tissue repair, wound remodeling and antimicrobial host defense, or pathologic processes such as atherosclerosis, chronic inflammation or cancer (Wagner 2005; Rivera, Lozano *et al.* 2009; Leslie 2010). In all these processes, platelets act as sentinels capable of responding rapidly to chemical changes in their environment.

Under physiological conditions, platelets circulate in the blood in a quiescent state and their activation is inhibited by both, nitric oxide and prostacyclin released from endothelial cells. However, after vascular injury, platelets become activated and provide rapid protection against bleeding and catalyze the slower formation of stable blood clots via the coagulation cascade. In the initiation phase of primary hemostasis, platelets roll, adhere, and spread on the collagen matrix to form an activated platelet monolayer. During the rolling phase, adhesion is mediated mainly by the interaction between the glycoprotein (GP) Ib/V/IX receptor complex on the platelet surface with von Willebrand Factor (vWF), and between the GPIIb/IIIa and integrin  $\alpha$ IIb $\beta$ 3 proteins with collagen present in the exposed subendothelium. These interactions allow the arrest and activation of adherent platelets. Platelet adhesion triggers the release of soluble mediators such as adenosine 5-diphosphate (ADP), thromboxane A<sub>2</sub> (TXA<sub>2</sub>) and serotonin, which in combination with the locally generated thrombin, allow the formation of platelet-platelet aggregates and the recruitment of additional circulating platelets which extend and stabilize the hemostatic plug. Specific interactions of these agonists with their G-protein coupled receptors generate inside-out signaling leading to the conformational activation of integrins, in particular  $\alpha$ IIb $\beta$ 3, increasing their ligand affinity (Angiolillo, Ueno *et al.* 2010). Binding of  $\alpha$ IIb $\beta$ 3 to its ligands, mainly fibrinogen, supports processes such as clot retraction, platelet aggregation and secretion of the granule proteins (Ma, Qin *et al.* 2007; Rivera, Lozano *et al.* 2009). Platelets contain four types of storage compartments –  $\alpha$ -granules, dense granules, peroxisomes and lysosomes – whose contents are released into the circulation. When stimulated by thrombin, the platelet releasate contains > 300 proteins including prothrombotic substances, growth factors, chemokines and proteases. Although the release of cargo during exocytosis delivers many proteins into the circulation, the process also alters the composition of the platelet membrane, resulting in surface expression of P-selectin and an

increase in the number of integrin  $\alpha\text{IIb}\beta 3$  molecules (Nurden, Nurden *et al.* 2008). The exposure of P-selectin is especially important for platelet-leukocyte and platelet-endothelial interactions, as this molecule mediates the initial interactions of leukocytes and endothelium with activated platelets (Wagner 2005).

The ability of platelets to store and release such a variety of bioactive mediators allows them to play an important role in modulating the function of other cells and explains why platelets are also critically involved in other biological processes beyond hemostasis.

## Galectins

Galectins are evolutionarily-conserved lectins defined by at least one carbohydrate recognition domain (CRD) with affinity for  $\beta$ -galactosides and conserved sequence motifs. These lectins are found in almost all organisms and to date 15 galectins have been found in mammals; although only 12 galectin genes are found in humans. On the basis of their molecular structure, galectins are classified into three main types: ‘proto-type’ galectins, comprising a single polypeptide chain that is able to dimerize (galectin-1, -2, -5, -7, -10, -11, -13, -14, and -15); ‘tandem repeat-type’ galectins, composed of a single polypeptide chain presenting two CRDs connected by a linker peptide (galectin-4, -6, -8, -9, and -12); and the ‘chimera-type’ galectin-3, which consists of one C-terminal CRD linked to an N-terminal peptide. A more recent classification based on gene sequence comparisons and intron–exon position analysis has classified galectins’ CRDs into two distinct subgroups (F3 and F4). Peculiarly, bi-CRD galectins usually display one domain of each type, F3 and F4 (Di Lella, Sundblad *et al.* 2011). Although most galectins bind N-acetyllactosamine [ $\text{Gal}\beta 1\text{-4-NAcGlc}$ ] units, important differences in glycan binding preferences among different members of the family have been reported (Rabinovich and Toscano 2009). Galectins function, either intracellularly or extracellularly, as key biological mediators capable of monitoring changes occurring on the cell surface during fundamental biological processes such as cellular communication, inflammation, wound healing, development, and differentiation. They also play unique roles in intracellular signaling pathways, regulation of RNA splicing, cell cycle control, and control of apoptotic signaling, endocytosis machinery, and trafficking (Di Lella, Sundblad *et al.* 2011). Galectins can influence the capacity of innate immune cells (e.g., neutrophils, dendritic cells, monocytes/macrophages, eosinophils, and mast cells) to respond to chemotactic gradients, migrate across endothelial cell surfaces, synthesize and release both

pro- and anti-inflammatory mediators, and recognize, engulf, and kill microbes and damaged cells. In this regard, similar to alarmins some members of the galectin family contribute to trigger innate immune responses, while others influence the resolution of acute inflammation. Besides, galectins can bind glycans on the surface of pathogenic microbes coupling recognition processes to innate immunity (Davicino, Elicabe *et al.* 2011).

In spite of lack of a typical leader peptide required for secretion, galectins are released onto the extracellular milieu through an unusual, mostly unresolved mechanisms, where they play key roles as soluble mediators of various cell functions. In fact, galectins have been proposed to exert biological activities by forming supramolecular structures, termed 'lattices' with cell surface N- and O-glycans (Rabinovich, Toscano *et al.* 2007)

Most galectins are expressed in a wide variety of tissues. While some galectins (e.g., galectin-1 and -3) are widely expressed among different tissues of various species, other family members have a more restricted tissue localization and compartmentalization (e.g., galectin-7 is preferentially found in the skin, galectin-12 abundantly expressed in adipose tissue, galectin-5 restricted to rat reticulocytes, and galectin-10 strongly represented in human eosinophils, where they play essential roles in the control of cell fate (Di Lella, Sundblad *et al.* 2011).

Most galectins are overexpressed in several types of tumors and their expression correlates with tumor progression, aggressiveness and metastatic phenotype (Liu and Rabinovich 2005). For example, galectin-1 overexpression contributes to tumor immune escape, modulates tumor cell migration and adhesion and influences tumor angiogenesis (Thijssen, Postel *et al.* 2006). High expression of galectin-8 is associated with malignancy in some type of tumors such as colon and lung and, preliminary studies showed that inhibition of galectin-8 promotes tumor regression (Bidon-Wagner and Le Pennec 2004).

### **Platelet activation responses induced by galectin- 1 and -8**

Hemostasis and pathological thrombus formation are dynamic processes that require a coordinated series of events involving platelet membrane receptors, bidirectional intracellular signals, and release of platelet proteins and inflammatory substances. Platelet activation can be triggered by a broad spectrum of vascular adhesive proteins such as vWF, collagen, fibronectin and soluble agonists including ADP, TXA<sub>2</sub>, thrombin and serotonin. (Rivera,

Lozano *et al.* 2009). It has been recently shown that two structurally different members of the galectin family of proteins, galectin-1 and 8 are potent platelet agonists (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010; Romaniuk, Croci *et al.* 2012). Through the interaction with the carbohydrate backbone of the major platelet receptors involved in hemostasis, e.g.: GPIbVIX complex and integrin  $\alpha$ IIB $\beta$ 3, both galectins are capable to induce all the myriad of platelet responses including adhesion and spreading, aggregation, release of their granule content and the expression of P-selectin on the platelet membrane (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010; Romaniuk, Croci *et al.* 2012).

## Platelet receptors for galectin-1 and galectin 8

Most of the extracellular functions mediated by galectins involve the interaction of these proteins with different cell surface glycoconjugates containing repeating units of N-acetyllactosamine [Gal $\beta$ 1,4GlcNAc] as well as extracellular matrix proteins. Among the different receptors, integrins are known to be involved in galectin-mediated biological responses (Rabinovich, Toscano *et al.* 2007). Platelet activation mediated by galectin-1 or galectin-8 is prevented by lactose but not by sucrose indicating the interaction of these lectins with specific carbohydrate ligands on the platelet surface. MALDI/TOF mass spectrometry analyses determined that both galectins binds the subunit  $\alpha$ IIB from the  $\alpha$ IIB $\beta$ 3 integrin (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010). Additionally, while galectin-8 also binds GPIb and V from GPIb-IX-V complex (Romaniuk, Tribulatti *et al.* 2010), galectin-1 interacts with  $\alpha$ 6 $\beta$ 1. However, the use of platelets derived from patients who are deficient in  $\alpha$ IIB $\beta$ 3 or in GPIb, revealed that only GPIb and integrin  $\alpha$ IIB $\beta$ 3 are essential for galectin-8- and 1 dependent signal transduction respectively, and therefore represent functional counter-receptors (Romaniuk, Tribulatti *et al.* 2010; Romaniuk, Croci *et al.* 2012).

Similar to other integrins, the function of platelet  $\alpha$ IIB $\beta$ 3 is regulated by inside-out or outside-in signaling. Inside-out signaling occurs in response to binding of one or more platelet agonists and leads to the conversion of  $\alpha$ IIB $\beta$ 3 from a low-affinity/avidity receptor to a high-affinity/avidity receptor, thereby allowing engagement of soluble multivalent adhesive ligands, such as fibrinogen and vWF. Ligand binding to the integrin triggers another cascade of signals known as outside-in, which leads to irreversible adhesion and aggregation (Ma, Qin *et al.* 2007). In this context, galectin-1 acts as a peculiar agonist as it is capable of triggering platelet activation through outside-in signaling via direct binding to  $\alpha$ IIB $\beta$ 3 integrin. This

intrinsic property of galectin-1 may be associated to a general feature of galectins, which has been proposed to form ordered arrays of supramolecular structures composed of multivalent glycans and lectins (often termed “lattices”) on the cell surface (Yang, Rabinovich *et al.* 2008). Thus, it is conceivable that galectin-1 binding to  $\alpha\text{IIb}\beta_3$  integrin forms lattices that induce integrin clustering that leads to platelet signaling and activation.

## Signaling pathways involved in galectin-mediated platelet activation

Although the model of how GPIb–GPIX–GPV signals in human platelets is currently incomplete, the activation of Src, PI3K, PLC $\gamma$  2 and ERK appears to be involved in GPIb activation mediated by vWF binding, its major ligand (Ozaki, Asazuma *et al.* 2005). In accordance with the notion that GPIb is an essential receptor for transducing galectin-8 signaling, platelet stimulation by galectin-8 results in phosphorylation of PLC $\gamma$ 2, ERK1/2 and Akt. The phosphorylation of PLC $\gamma$ 2 and Akt appear to be relevant for platelet activation induced by galectin-8 since platelet aggregation is impaired in the presence of specific inhibitors of PLC and PI3K but not of MAPKK (Romaniuk, Tribulatti *et al.* 2010).

Downstream signals involved in galectin-1 binding to platelets include the most common signals elicited by soluble or adhesive agonists that induce activation of  $\alpha\text{IIb}\beta_3$  integrin, such as  $\text{Ca}^{2+}$  mobilization and phosphorylation of PLC $\gamma$ , Syk, mitogen-activated protein kinases (MAPKs), Akt, and  $\beta_3$  integrin. Tyrosine phosphorylation of the integrin tyrosine cytoplasmic motif of the  $\beta_3$  subunit is one of the most proximal and specific signaling events occurring after ligand binding to  $\alpha\text{IIb}\beta_3$  integrin and it is evident *in vitro* only under stirring conditions that allow integrin clustering or on platelet adhesion to immobilized fibrinogen (Ma, Qin *et al.* 2007). Galectin-1-induced phosphorylation of  $\beta_3$  integrin occurs rapidly in addition of galectin-1 to platelet suspensions. Moreover, rapid tyrosine phosphorylation of Syk, PLC $\gamma$ 2, and Akt (signaling events involved in platelet outside-in signaling) was also observed after platelet exposure to soluble galectin-1 (Romaniuk, Croci *et al.* 2012). Interestingly, phosphorylation of these kinases has been described on platelet stimulation with concanavalin A, a plant lectin with different glycan specificity but similar conformation and topology that triggers platelet activation by inducing clustering of  $\alpha\text{IIb}\beta_3$  integrin molecules (Torti, Festetics *et al.* 1999).



## Galectin-1 and galectin-8 trigger platelet aggregation

The capacity of platelets to form a thrombus depends on their ability to aggregate. At the molecular level, platelet aggregation is mediated by a specific receptor on the platelet surface: the  $\alpha\text{IIb}\beta 3$  integrin (Rivera, Lozano *et al.* 2009). Like most traditional platelet agonists, both soluble galectin-1 and galectin-8 promote the transition of this integrin from a low-affinity state (resting state) to a high-affinity state (active state), which results in the unmasking of neoepitopes in the  $\alpha\text{IIb}\beta 3$  complex, and allows fibrinogen binding which acts as a bridging molecule between platelets to form aggregates. This conformational change of  $\alpha\text{IIb}\beta 3$  integrin triggered by galectins is accompanied by a raise in intracellular calcium levels as well as morphological changes of platelets involving the rearrangement of the cytoskeleton including extension of filopodia and lamellipodia (spreading) and F-actin polymerization (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010).

Both, galectin-1 and galectin-8 induce aggregation of platelets suspended either in plasma or buffer, which indicates a relevant role of these lectins in physiological media. Although cell agglutination was one of the first biological activities described for these lectins, this effect on platelets was only observed at high galectin-1 and galectin-8 concentrations. Platelet aggregation at lower concentrations is absent in fixed platelets, in the presence of calcium chelating agents, or eptifibatide (an  $\alpha\text{IIb}\beta 3$  antagonist), implying that platelet responses mediated by galectins could be related either to cell activation or to a clustering effect of platelet surface receptors depending on their concentration (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010). Although both galectins were capable of promoting aggregation, galectin-8 was found to be ten times more potent than galectin-1 in this stimulatory effect. Although the dimeric structure of galectin-8 would anticipate a more robust effect of this galectin compared to galectin-1, the observation that only the N-terminal domain was also able to trigger platelet activation indicates that lectin bivalency is not essential to promote activating effects on platelets. The differences in the concentration required to achieve a similar effect, could therefore reflect different downstream molecular signals triggered by each galectins (Romaniuk, Tribulatti *et al.* 2010; Romaniuk, Negrotto *et al.* 2011).

The initial formation of platelet thrombus is rapidly reinforced by the generation and release of platelet TXA<sub>2</sub> and ADP (the main metabolite of arachidonic acid by the cyclooxygenase pathway, and a component of platelet dense granules respectively) which acting in a paracrine and autocrine manner promote further platelet activation (Rivera, Lozano *et al.* 2009). Both

molecules are generated on platelet stimulation by galectin-1 and -8 (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010). Moreover, although the aggregation response triggered by low galectin-8 concentrations was inhibited in the presence of aspirin (cyclooxygenase inhibitor) and/or an ADP-scavenger, a full response was obtained at higher concentrations indicating that galectin-8 is a strong agonist that activate platelets independently from TXA<sub>2</sub> formation or ADP release (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010).

### **Proinflammatory and procoagulant platelet-mediated responses induced by galectins**

The role of platelets in inflammation and vascular repair is mainly associated to the release of their alpha granule content, which includes among others, cell adhesion molecules that favor platelet/endothelial and leukocyte interaction, prothrombotic substances, and angiogenesis regulatory growth factors (May, Seizer *et al.* 2008; Etulain J 2012).

Galectin-1 and -8 are strong inducers of P-selectin expression (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010). The major role of P-selectin on the platelet surface is the interaction with PSGL-1, its major counter-receptor on leukocytes, to form platelet-leukocyte aggregates (Wagner 2005). In fact, activation of platelets by galectin-1 in the presence of polymorphonuclear leukocytes results in a significant formation of heterotypic cell aggregates (Pacienza, Pozner *et al.* 2008). This interaction promotes activation of both cell types, which is a crucial condition for triggering inflammation, vascular remodeling and thrombosis. The expression of P-selectin on the platelet surface, the formation of leukocyte-platelets aggregates and leukocyte activation, are relevant events in acute syndromes including coronary diseases as well as in deep vein thrombosis (DVT) (Dotsenko, Chaturvedi *et al.* 2007; Etulain J 2012). Given that galectins promote all these responses, binding of these lectins to platelets might represent potentially novel mechanism involved in both, arterial and venous thrombosis.

In a cancer setting, the formation of heterotypic aggregates between circulating tumor cells overexpressing galectin-1 or -8 and platelets would result in P-selectin expression, which may contribute to the metastatic properties of these galectins by promoting stable adhesion to the endothelium and/or transmigration of tumor cells outside of the vasculature.

vWF is a large multimeric glycoprotein that allows platelet-endothelium, platelet-subendothelium and platelet-platelet interaction and is therefore important for platelet adhesion and thrombus formation. Similarly to P-selectin, vWF is stored in platelet  $\alpha$ -granules and in Weibel-Palade bodies of endothelial cells from which is released during injury or inflammation. vWF is a biomarker for endothelial dysfunction and cardiovascular risk and high levels of vWF are found in both chronic and acute inflammation (Luo, Ni *et al.* 2012). The release of vWF occurs after activation of platelets by galectin-1 (unpublished data) and -8 (Romaniuk, Tribulatti *et al.* 2010). Thus, P-selectin expression and vWF release mediated by galectins might play an important role in the pathogenesis of thrombus formation and the modulation of inflammatory responses.

While galectin-8 has been linked to proinflammatory processes (Cattaneo, Tribulatti *et al.* 2011), both, anti and proinflammatory activities have been described for galectin-1 (Liu and Rabinovich 2010). Whether anti-inflammatory and pro-inflammatory effects occur at different concentrations of galectin-1 still remains to be established. The fact that galectin-1 promotes platelet activation support to the notion that under certain circumstances, galectin-1 could also act as a pro-inflammatory factor.

Vesiculation of the platelet membrane and formation of platelet microparticles (PMPs) is a characteristic effect of certain agonists such as collagen, thrombin or C5b-9 complement fragment. PMPs are released not only during platelet activation *in vitro* but are also detected *in vivo* (Morel, Toti *et al.* 2006). They are thought to provide catalytic surface for several enzyme complexes of the coagulation system and to underlie the pro-coagulant responses elicited by platelet activation. Moreover, PMPs may themselves evoke cellular responses in the immediate microenvironment including platelet adhesion to the site of endothelial injury and angiogenesis. The ability of galectin-1 to induce phosphatidylserine-expressing PMPs (Pacienza, Pozner *et al.* 2008) suggests that this lectin not only promotes platelet activation, but could also indirectly activates the coagulation cascade.

### Galectins and platelet adhesion

Platelet adhesion and spreading, together with cytoskeletal rearrangements, are early functional responses that occur upon vascular injury as a consequence of outside-in signaling on ligand binding to  $\alpha_{IIb}\beta_3$  and integrin oligomerization (Rivera, Lozano *et al.* 2009). Platelet

adhesion to the extracellular matrix at sites of vascular injury represents a key step for limiting bleeding but, if uncontrolled, can lead to occlusion. Immobilized galectin-1 and -8 are efficient substrates for platelet adhesion, filopodia, and lamellipodia formation in the absence of additional platelet agonists (Pacienza, Pozner *et al.* 2008; Romaniuk, Croci *et al.* 2012). The demonstration that immobilized galectins are as efficient as their soluble form in triggering platelet activation together with the observation that their expression is increased in activated endothelium or tumor cells (Thijssen, Hulsmans *et al.* 2008), suggest that the interaction of platelets with immobilized galectin-1 or -8 could be relevant in different clinical settings, including not only vascular but also inflammatory disorders such as atherosclerosis and cancer. Several studies demonstrated that galectins including galectin-1 and -8 participate in the initiation, progression and rupture of an atheroma plaque (Al-Ansari, Zeebregts *et al.* 2009). Galectins expressed in the inner of atheroma plaque, may not only influence platelet activation but may also serve as key components of the extremely thrombogenic core exposed after plaque rupture, the main trigger for acute thrombus formation and the cause of unstable angina, myocardial infarction, transient ischemic attack and stroke (May, Seizer *et al.* 2008).

In cancer, platelets are known to contribute to tumor progression and metastasis. One of the mechanisms underlying this effect is the formation of mixed-cell aggregates between tumor cells expressing mucins and platelets expressing P-selectin; these complexes prevent tumor cell attack by the immune system (Leslie 2010). In the same line of evidence, the interaction between tumor cells expressing high levels of galectins and platelets could represent another molecular mechanism through which both, platelets and galectins promote the metastatic cascade. Interestingly and in contrast to mucin-P-selectin interactions, the interaction of tumor cells with platelets via galectins would not require the presence of activated platelets. Furthermore, the overexpression of galectins in tumor cells could also represent a trigger for platelet activation allowing the release of  $\alpha$ -granules content including growth factors, which can promote tumor progression and angiogenesis.

### **Platelets express galectin-1 and galectin-8**

In addition to vascular cells, human platelets express substantial levels of galectin-1 and -8 (Pacienza, Pozner *et al.* 2008; Romaniuk, Tribulatti *et al.* 2010). Although both galectins are secreted proteins, they are mainly found in the cytosol of different cell types. Human platelets express the two splice variants of galectin-8. Moreover, whereas galectin-8, like P-selectin, is

absent on the surface of resting platelets, it is exposed on the membrane of thrombin-stimulated platelets (Romaniuk, Tribulatti *et al.* 2010). This finding suggests that in the vascular system, platelets are another source of galectin-8 that would be accessible upon platelet activation to eventually promote thrombus growth. Furthermore, it has been recently shown that galectin-8 regulates platelet function by mediating the uptake of platelet proteins (i.e. FV) by megakaryocytes (Zappelli, van der Zwaan *et al.* 2012). In contrast, galectin-1 is not expressed on the platelet surface upon activation (unpublished observations). The differences between both galectins are still not clear. Interestingly, addition of lactose and thiodigalactoside partially prevents aggregation induced by classical agonists suggesting that platelet-derived galectins and their glycans might contribute to platelet activation.

Thrombosis and disseminated intravascular coagulation are common complications in cancer patients. A hypercoagulable or pro-thrombotic state of malignancy occurs due to the ability of tumor cells to activate platelets and the coagulation system. Pro-thrombotic factors in cancer include the ability of tumor cells to produce and secrete pro-coagulant/fibrinolytic substances and pro-inflammatory cytokines and the physical interaction between tumor cells and platelets. However, the mechanisms allowing the occurrence of prothrombotic states in cancer patients are not completely understood.

The observed increased of galectin-1 and -8 in tumoral endothelial cells as well as in other malignant cells could represent a pathogenic mechanism involved in thrombosis and disseminated intravascular coagulation complications. Given the pivotal role of galectin-1 and -8 in tumor progression, it could be conceivable that galectin-induced platelet activation might contribute to the pathogenesis of thrombosis in cancer patients

### **Galectin-1 plays a role in normal primary hemostasis**

The relevance of galectin-1 in hemostasis, has been recently studied in galectin-1 null mutant mice. Animals deficient in galectin-1 had prolonged bleeding time, an effect which was not associated with a decrease in platelet number but rather to a platelet dysfunction. In fact, galectin-1-deficient platelets showed a restricted adhesion to immobilized fibrinogen and a delayed clot retraction, two platelet activation responses dependent on outside-in signaling of platelet integrin  $\alpha\text{IIb}\beta 3$  (Romaniuk, Croci *et al.* 2012). Thus, an impairment of this activation pathway appears to be a major cause of the altered bleeding time in mice lacking galectin-1.

Interestingly, many of the hemostatic alterations present in mice with galectin-1 ablation recapitulate the phenotypes observed in mice devoid of the tetraspanin superfamily member TSSC6 or in mice in which the integrin cytoplasmic tyrosine motif has been mutated to phenylalanine, which all exhibited impaired outside-in signaling (Romaniuk, Croci *et al.* 2012). The concept that galectin-1 has a role in hemostasis was also recently described by Saint-Lu N *et al.* who showed that galectin-1/galectin-3 double-deficient mice are characterized by a more rapid formation of initial thrombi following ferric chloride-induced injury, but less stable occlusive thrombi compared with those of wild-type mice (Saint-Lu, Oortwijn *et al.* 2012).

## Conclusions

Over the last decade we have witnessed significant advances regarding the biology of galectins and their role in cellular homeostasis. Particularly considerable progress has been made on the contribution of galectins to innate and adaptive immune responses. The information currently available indicates that galectins are expressed and secreted by several cell types in normal and pathologic conditions. The emerging evidence showing that galectins are also capable of triggering platelet activation opens a completely new field of research where so far there are more questions than answers. From a more general perspective, this field will also uncover the role of glycans and glycosyltransferases in platelet function and hemostasis. The study of galectin-glycan interactions in platelet activation will provide further insight into the mechanisms linking inflammatory mediators to thrombus formation and could expand our view of the role of platelets much beyond homeostasis to their pathophysiologic role during inflammation and cancer.

## Acknowledgements

Work in M.S's. and G.A.R's laboratories is supported by grants from the National Agency for Promotion of Science and Technology (Argentina) and National Council for Scientific and Technical Investigation (CONICET, Argentina). Work in G.A.R's lab is supported by Sales Foundation for Cancer (Argentina), University of Buenos Aires (Argentina), and National Multiple Sclerosis Society (USA).

## References

- Al-Ansari, S., C. J. Zeebregts, *et al.* (2009). "Galectins in atherosclerotic disease." *Trends Cardiovasc Med* 19(5): 164-169.
- Angiolillo, D. J., M. Ueno, *et al.* (2010). "Basic principles of platelet biology and clinical implications." *Circ J* 74(4): 597-607.
- Bidon-Wagner, N. and J. P. Le Pennec (2004). "Human galectin-8 isoforms and cancer." *Glycoconj J* 19(7-9): 557-563.
- Cattaneo, V., M. V. Tribulatti, *et al.* (2011). "Galectin-8 tandem-repeat structure is essential for T-cell proliferation but not for co-stimulation." *Biochem J* 434(1): 153-160.
- Davicino, R. C., R. J. Elicabe, *et al.* (2011). "Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms." *Int Immunopharmacol* 11(10): 1457-1463.
- Di Lella, S., V. Sundblad, *et al.* (2011). "When galectins recognize glycans: from biochemistry to physiology and back again." *Biochemistry* 50(37): 7842-7857.
- Dotsenko, O., N. Chaturvedi, *et al.* (2007). "Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men." *J Thromb Haemost* 5(10): 2036-2042.
- Etulain J, S. M. (2012). "Current viewpoints on platelet contribution to inflammation." *World Journal of Hematology* 1(4): 14-21.
- Leslie, M. (2010). "Cell biology. Beyond clotting: the powers of platelets." *Science* 328(5978): 562-564.
- Liu, F. T. and G. A. Rabinovich (2005). "Galectins as modulators of tumour progression." *Nat. Rev. Cancer* 5(1): 29-41.
- Liu, F. T. and G. A. Rabinovich (2010). "Galectins: regulators of acute and chronic inflammation." *Ann N Y Acad Sci* 1183: 158-182.
- Luo, G. P., B. Ni, *et al.* (2012). "von Willebrand factor: more than a regulator of hemostasis and thrombosis." *Acta Haematol* 128(3): 158-169.
- Ma, Y. Q., J. Qin, *et al.* (2007). "Platelet integrin alpha(IIb)beta(3): activation mechanisms." *J Thromb Haemost* 5(7): 1345-1352.
- May, A. E., P. Seizer, *et al.* (2008). "Platelets: inflammatory firebugs of vascular walls." *Arterioscler Thromb Vasc Biol* 28(3): s5-10.
- Morel, O., F. Toti, *et al.* (2006). "Procoagulant microparticles: disrupting the vascular homeostasis equation?" *Arterioscler Thromb Vasc Biol* 26(12): 2594-2604.
- Nurden, A. T., P. Nurden, *et al.* (2008). "Platelets and wound healing." *Front Biosci* 13: 3532-3548.
- Ozaki, Y., N. Asazuma, *et al.* (2005). "Platelet GPIb-IX-V-dependent signaling." *J Thromb Haemost* 3(8): 1745-1751.
- Pacienza, N., R. G. Pozner, *et al.* (2008). "The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation." *Faseb J* 22(4): 1113-1123.

- Rabinovich, G. A. and M. A. Toscano (2009). "Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation." *Nat Rev Immunol* 9(5): 338-352.
- Rabinovich, G. A., M. A. Toscano, *et al.* (2007). "Functions of cell surface galectin-glycoprotein lattices." *Curr Opin Struct Biol* 17(5): 513-520.
- Rivera, J., M. L. Lozano, *et al.* (2009). "Platelet receptors and signaling in the dynamics of thrombus formation." *Haematologica* 94(5): 700-711.
- Romaniuk, M. A., D. O. Croci, *et al.* (2012). "Binding of galectin-1 to alphaIIb beta(3) integrin triggers "outside-in" signals, stimulates platelet activation, and controls primary hemostasis." *Faseb J* 26(7): 2788-2798.
- Romaniuk, M. A., S. Negrotto, *et al.* (2011). "Identification of galectins as novel regulators of platelet signaling and function." *IUBMB Life* 63(7): 521-527.
- Romaniuk, M. A., M. V. Tribulatti, *et al.* (2010). "Human platelets express and are activated by galectin-8." *Biochem J* 432(3): 535-547.
- Saint-Lu, N., B. D. Oortwijn, *et al.* (2012). "Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor." *Arterioscler Thromb Vasc Biol* 32(4): 894-901.
- Thijssen, V. L., S. Hulsmans, *et al.* (2008). "The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells." *Am J Pathol* 172(2): 545-553.
- Thijssen, V. L., R. Postel, *et al.* (2006). "Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy." *Proc Natl Acad Sci U S A* 103(43): 15975-15980.
- Torti, M., E. T. Festetics, *et al.* (1999). "Clustering of integrin alphaIIb-beta3 differently regulates tyrosine phosphorylation of pp72syk, PLCgamma2 and pp125FAK in concanavalin A-stimulated platelets." *Thromb Haemost* 81(1): 124-130.
- Wagner, D. D. (2005). "New links between inflammation and thrombosis." *Arterioscler Thromb Vasc Biol* 25(7): 1321-1324. Epub 2005 Apr 13 14.
- Yang, R. Y., G. A. Rabinovich, *et al.* (2008). "Galectins: structure, function and therapeutic potential." *Expert Rev Mol Med* 10: e17.
- Zappelli, C., C. van der Zwaan, *et al.* (2012). "Novel role for galectin-8 protein as mediator of coagulation factor V endocytosis by megakaryocytes." *J Biol Chem* 287(11): 8327-8335.